Joris van Arensbergen,PhD
Founder & CEO
Joris van Arensbergen entered the biotechnology industry in 2017 when he decided to commercialize the SuRE technology that he developed during his time as a postdoctoral researcher at the Netherlands Cancer Institute. Joris has a background in the field of transcriptional regulation.
